https://www.sciencedaily.com/releases/2012/09/120906141854.htm
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival...
second lineresponse rateaddingbavituximabchemotherapy